Brief: NGM Biopharmaceuticals Expects To Report It Had About $300 Mln Cash, Cash Equivalents & Short-Term Marketable Securities As Of Sept 30
17/10/2022 13:20
Oct 17 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIOPHARMACEUTICALS - CO EXPECTS TO REPORT IT HAD ABOUT
$300
MILLION OF CASH, CASH EQUIVALENTS & SHORT-TERM MARKETABLE
SECURITIES AS OF SEPT 30
Source text for Eikon: ID:nFWN31I293
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors